Mederi Therapeutics announce new registry for Stretta Therapy to treat gastroesophageal reflux disease.

Mederi Therapeutics has announced a new multi-center registry that will study the benefit of Stretta Therapy as a treatment option in patients who experience gastroesophageal reflux disease (GERD) after sleeve gastrectomy (SG). The study, entitled "Examining the Benefit of RF Treatment (Stretta) of GERD after Sleeve Gastrectomy," includes 15 of the top bariatric programs in the U.S. This multi-center registry will study patients with documented GERD a minimum of six months after a sleeve gastrectomy. The study will focus on GERD symptom control (HRQL) after Stretta, with follow up at six, 12, and 24 months.

Comment:The Stretta Procedure is an endoscopically-guided, minimally invasive, outpatient procedure performed in approximately 60 minutes. The Stretta Catheter, powered by the Mederi Radiofrequency Generator, is an innovative design for simple, precise and safe delivery of radiofrequency energy to the lower esophageal sphincter (LES) muscle and gastric cardia. This treatment has been shown to remodel tissue and improve the barrier function and motility of the LES, reducing the frequency and severity of reflux events. There is no hospital stay involved with the Stretta Procedure and patients are typically able to return to normal activities the following day.